Palisade Bio (PALI) Shares Outstanding (Weighted Average) (2010 - 2026)
Palisade Bio (PALI) reported Shares Outstanding (Weighted Average) of $209.7 million for Q1 2026, up 4271.97% year-over-year from $4.8 million in Q1 2025, and up 276.62% quarter-over-quarter from $55.7 million in Q4 2025.
Palisade Bio (PALI) Shares Outstanding (Weighted Average) (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $209.7 million in Q1 2026.
- Shares Outstanding (Weighted Average) for Q1 2026 came in at $209.7 million, up 4271.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $209.7 million (up 4271.97% YoY), and the FY2025 annual result was $55.7 million, up 3830.18% from the prior year.
- Shares Outstanding (Weighted Average) rose to $209.7 million in Q1 2026 per PALI's latest filing, from $55.7 million in the prior quarter.
- Over five years, Shares Outstanding (Weighted Average) peaked at $209.7 million in Q1 2026 and troughed at $287702.0 in Q1 2023.
- A 5-year average of $17.2 million and a median of $880311.0 in 2022 frame the typical range for Shares Outstanding (Weighted Average).
- The sharpest annual moves came in 2022 and 2026: Shares Outstanding (Weighted Average) sank 93.01% in 2022, then soared 4271.97% in 2026.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $880311.0 in 2022, then tumbled by 48.2% to $456014.0 in 2023, then soared by 210.62% to $1.4 million in 2024, then soared by 3830.18% to $55.7 million in 2025, then soared by 276.62% to $209.7 million in 2026.
- Business Quant data shows PALI's Shares Outstanding (Weighted Average) at $209.7 million in Q1 2026, $55.7 million in Q4 2025, and $9.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 417.01 Bn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 928.40 Mn |
| 10 | Palisade Bio | 357.48 Mn | 227.91 Mn | - | 209.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 209.66 Mn |
| Dec 31, 2025 | 55.67 Mn |
| Sep 30, 2025 | 9.30 Mn |
| Jun 30, 2025 | 4.80 Mn |
| Mar 31, 2025 | 4.80 Mn |
| Dec 31, 2024 | 1.42 Mn |
| Sep 30, 2024 | 1.17 Mn |
| Jun 30, 2024 | 1.00 Mn |
| Mar 31, 2024 | 768,137.00 |
| Dec 31, 2023 | 456,014.00 |
| Sep 30, 2023 | 489,624.00 |
| Jun 30, 2023 | 357,572.00 |
| Mar 31, 2023 | 287,702.00 |
| Dec 31, 2022 | 880,311.00 |
| Sep 30, 2022 | 572,684.00 |
| Jun 30, 2022 | 405,893.00 |
| Mar 31, 2022 | 324,473.00 |
| Dec 31, 2021 | 186,195.00 |
| Sep 30, 2021 | 7.90 Mn |
| Jun 30, 2021 | 5.80 Mn |